Cantel Medical Corp. (NYSE:CMN) CAO Steven C. Anaya sold 5,500 shares of the business’s stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $77.07, for a total transaction of $423,885.00. Following the completion of the transaction, the chief accounting officer now directly owns 48,132 shares in the company, valued at $3,709,533.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Shares of Cantel Medical Corp. (NYSE:CMN) opened at 75.56 on Monday. The company has a 50-day moving average price of $77.84 and a 200-day moving average price of $71.26. The company has a market capitalization of $3.13 billion, a PE ratio of 52.55 and a beta of 1.59. Cantel Medical Corp. has a 52 week low of $55.01 and a 52 week high of $81.63.
Cantel Medical Corp. (NYSE:CMN) last posted its quarterly earnings data on Thursday, September 29th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.11. The business earned $179 million during the quarter. Cantel Medical Corp. had a return on equity of 16.70% and a net margin of 9.02%. Cantel Medical Corp.’s revenue for the quarter was up 18.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.39 EPS. Analysts predict that Cantel Medical Corp. will post $1.98 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the company. Acrospire Investment Management LLC increased its position in Cantel Medical Corp. by 51.2% in the second quarter. Acrospire Investment Management LLC now owns 1,477 shares of the company’s stock worth $102,000 after buying an additional 500 shares during the period. LS Investment Advisors LLC increased its position in shares of Cantel Medical Corp. by 7.5% in the second quarter. LS Investment Advisors LLC now owns 1,510 shares of the company’s stock valued at $104,000 after buying an additional 106 shares during the last quarter. Integrated Investment Consultants LLC increased its position in shares of Cantel Medical Corp. by 2.1% in the third quarter. Integrated Investment Consultants LLC now owns 2,033 shares of the company’s stock valued at $153,000 after buying an additional 41 shares during the last quarter. BlackRock Inc. increased its position in shares of Cantel Medical Corp. by 119.5% in the first quarter. BlackRock Inc. now owns 2,355 shares of the company’s stock valued at $168,000 after buying an additional 1,282 shares during the last quarter. Finally, Bank of Montreal Can bought a new position in shares of Cantel Medical Corp. during the second quarter valued at $203,000. Institutional investors and hedge funds own 81.61% of the company’s stock.
A number of equities analysts recently weighed in on the stock. Needham & Company LLC assumed coverage on shares of Cantel Medical Corp. in a report on Wednesday, August 24th. They issued a “hold” rating on the stock. Benchmark Co. started coverage on Cantel Medical Corp. in a research note on Monday, August 29th. They issued a “buy” rating and a $83.00 price objective on the stock.
Cantel Medical Corp. Company Profile
Cantel Medical Corp. is a provider of infection prevention and control products and services in the healthcare market. The Company’s segments include Endoscopy, Water Purification and Filtration, Healthcare Disposables, Dialysis and Specialty Packaging. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.